Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and activity of gemcitabine plus
trastuzumab and pertuzumab in patients with metastatic human epidermal growth factor receptor
2 (HER2)+ breast cancer who have progressed on at least one prior line of chemotherapy plus
HER2 targeted agent such as T-DM1, trastuzumab, or lapatinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute